Listed by the USPTO as CONNORS, ALEXANDRA F
Tech Center 1600 • Art Units: 1631 1632 1633 1634 1638
This examiner grants 24% of resolved cases
CONNORS, ALEXANDRA F is assigned to art unit 1631 in Tech Center 1600. The profile contains 114 resolved cases, a 23.7% allowance rate, and a median of 1549 days to allowance. The interview lift is 45.5%. The limited case record should temper predictive use, but the data show a low allowance rate, a strong positive interview association, and a lengthy median prosecution period.
The listed companies are University of Massachusetts, Fujifilm Corporation, and Globus Medical Inc. The leading firms are BAKER BOTTS L.L.P., Anderson Patent Law Firm LLC, and BALLARD SPAHR LLP. These participants provide context for the applications and representation reflected in the record.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18830890 | MANUFACTURING METHOD OF MIXED POWDER, MIXED POWDER, POWDER, AND POWDER MEDIUM | Non-Final OA | FUJIFILM Corporation |
| 17635047 | TARGETING OF THE CYTOSKELETON AS A THERAPEUTIC APPROACH FOR NEURODEGENERATIVE DISEASE | Final Rejection | University of Massachusetts |
| 18849747 | METHOD FOR PRESERVING CELLS | Non-Final OA | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE |
| 18320499 | BIOMATERIALS CONTAINING UMBILICAL CORD-DERIVED STEM CELLS | Non-Final OA | GLOBUS MEDICAL, INC. |
| 18051653 | TCF7L2 MEDIATED REMYELINATION IN THE BRAIN | Non-Final OA | University of Rochester |
| 18245128 | COMPOSITIONS AND METHODS OF USE FOR INFUSIBLE EXTRACELLULAR MATRIX | Non-Final OA | The Regents of the University of California |
| 18029875 | NOVEL NR1 ES-DERIVED NEURAL STEM CELLS HAVING A NORMAL KARYOTYPE AND USES THEREOF | Final Rejection | The Board of Trustees of the Leland Stanford Junior University |
| 19099556 | NOVEL PROMOTER | Non-Final OA | TOHOKU UNIVERSITY |
| 16314471 | PROPHYLACTIC OR THERAPEUTIC AGENT FOR ORGAN FIBROSIS | Non-Final OA | TOHOKU UNIVERSITY |
| 18223434 | VECTORS, GENETICALLY MODIFIED CELLS, AND GENETICALLY MODIFIED NON-HUMAN ANIMALS COMPRISING THE SAME | Non-Final OA | Regeneron Pharmaceuticals, Inc. |
| 17995687 | CONDITIONING REGIMENS FOR IN VIVO GENE THERAPY | Non-Final OA | University of Washington |
| 18301093 | Human Adipose-Derived Stem Cell Exosomes And Their Packaging For Use At Room Temperature | Final Rejection | The United States Government As Represented By The Department Of Veterans Affairs |
| 17224831 | METHODS OF TREATING INFLAMMATION | Non-Final OA | University of South Florida |
| 18043095 | ALGINATE-COATED MESENCHYMAL STROMAL AND PROGENITOR CELLS AND METHODS FOR USING THE SAME | Final Rejection | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS |
| 17416311 | ADENO-ASSOCIATED VIRUSES AND THEIR USES FOR INNER EAR THERAPY | Non-Final OA | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA |
| 16971995 | METHODS AND COMPOSITIONS COMPRISING CART AND A SMAC MIMETIC | Final Rejection | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA |
| 18850414 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF PARKINSON'S DISEASE | Non-Final OA | ASKBIO INC. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy23.7% of resolved applications examined by Alexandra F Connors were allowed (114 resolved cases), compared with 28.4% across Art Unit 1631 over the last five years.
This examiner's interview lift is +45.5 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.
Applications allowed by Alexandra F Connors took 1,549 days on average from filing to allowance.
Alexandra F Connors examines applications in Art Unit 1631 in Tech Center 1600 (Biotechnology & Pharmaceuticals).
